Publications

2017

• Activated protein C protects from GvHD via PAR2/PAR3 signalling in regulatory T-cells.
  Ranjan S, Goihl A, Kohli S, Gadi I, Pierau M, Shahzad K, Gupta D, Bock F, Wang H, Shaikh H, Kähne T, Reinhold D, Bank U, Zenclussen AC, Niemz J, Schnöder TM, Brunner-Weinzierl M, Fischer T, Kalinski T, Schraven B, Luft T, Huehn J, Naumann M, Heidel FH, Isermann B
  Nat Commun 2017, 8(1), 311
  
• Mitochondrial BAX Determines the Predisposition to Apoptosis in Human AML.
  Reichenbach F, Wiedenmann C, Schalk E, Becker D, Funk K, Scholz-Kreisel P, Todt F, Wolleschak D, Döhner K, Marquardt** JU, Heidel** F, Edlich** F
  Clin Cancer Res 2017, 23(16), 4805-16 ** co-corresponding authors
  
• Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis.
  Schlenk RF, Stegelmann F, Reiter A, Jost E, Gattermann N, Hebart H, Waller C, Hochhaus A, Platzbecker U, Schafhausen P, Blau IW, Verbeek W, Heidel FH, Werner M, Kreipe H, Teleanu V, Benner A, Döhner H, Grießhammer M, Döhner K
  Leukemia 2017, 31(4), 889-95
  
• Macrophage's little helper: vitamin A directs alternatively activated monocyte-derived macrophages to tissue-resident macrophages.
  Schlüter D, Heidel FH
  Cell Mol Immunol 2017, 14(10), 805-8
  
• Cell autonomous expression of CXCL-10 in JAK2V617F-mutated MPN.
  Schnöder TM, Eberhardt J, Koehler M, Bierhoff HB, Weinert S, Pandey AD, Nimmagadda SC, Wolleschak D, Jöhrens K, Fischer T, Heidel FH
  J Cancer Res Clin Oncol 2017, 143(5), 807-20
  
• Synergistic killing of FLT3ITD-positive AML cells by combined inhibition of tyrosine-kinase activity and N-glycosylation.
  Tsitsipatis D, Jayavelu AK, Müller JP, Bauer R, Schmidt-Arras D, Mahboobi S, Schnöder TM, Heidel F, Böhmer FD
  Oncotarget 2017, 8(16), 26613-24
  
• Nucleosome Positioning Assay
  Zhao Z, Bierhoff H
  Bio-protocol 2017, 7(10), e2285
  

2016

• Impact of FLT3-ITD location on sensitivity to TKI-therapy in vitro and in vivo.
  Arreba-Tutusaus P, Mack TS, Bullinger L, Schnöder TM, Polanetzki A, Weinert S, Ballaschk A, Wang Z, Deshpande AJ, Armstrong SA, Döhner K, Fischer T, Heidel FH
  Leukemia 2016, 30(5), 1220-5
  
• Expression and function of ABC-transporter protein ABCB1 correlates with inhibitory capacity of Ruxolitinib in vitro and in vivo.
  Ebert C, Perner F, Wolleschak D, Schnöder TM, Fischer T, Heidel FH
  Haematologica 2016, 101(3), e81-5
  
• Leukemogenic potency of the novel FLT3-N676K mutant.
  Huang K, Yang M, Pan Z, Heidel FH, Scherr M, Eder M, Fischer T, Büsche G, Welte K, von Neuhoff N, Ganser A, Li Z
  Ann Hematol 2016, 95(5), 783-91